A Phase 1b Study of Psilocybin Assisted Psychotherapy to Address Fear of Recurrence

This Phase Ib interventional trial (n=20) will test whether psilocybin (25mg) combined with psychotherapy can reduce fear of recurrence in women with early breast cancer and ovarian cancer in remission.

Conducted by the University of Colorado, Denver, this study aims to determine if psilocybin-assisted therapy can improve fear of cancer recurrence, anxiety, depression, and quality of life.

Participants will undergo preparatory therapy sessions, receive a moderately high dose of psilocybin in a monitored setting, and then complete four integration therapy sessions. Surveys will be used to measure changes in fear of recurrence, depression, anxiety, cancer-related existential distress, quality of life, and spirituality at various points up to 24 weeks.

The study, involving women aged 21 and older, will start in December 2024 and is expected to be completed by December 2028.

Topic Palliative Care Anxiety Depression
Compound Psilocybin
Country United States of America
Visit trial

Trial Details



Trial Number

Data attribution

A large set of the trials in our database are sourced from ClinicalTrials.gov (CTG). We have modified these post to display the information in a more clear format or to correct spelling mistakes. Our database in actively updated and may show a different status (e.g. completed) if we have knowledge of this update (e.g. a published paper on the study) which isn't reflected yet on CTG. If a trial is not sourced from CTG, this is indicated on this page and you can follow the link to the alternative source of information.